Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice